Rockefeller Capital Management L.P. Purchases New Shares in Genmab A/S Sponsored ADR $GMAB

Rockefeller Capital Management L.P. acquired a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,931 shares of the company’s stock, valued at approximately $267,000.

A number of other large investors have also recently made changes to their positions in GMAB. Headlands Technologies LLC raised its position in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after buying an additional 1,464 shares in the last quarter. CWM LLC raised its position in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after purchasing an additional 1,070 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Genmab A/S by 377.5% in the 2nd quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock worth $77,000 after purchasing an additional 2,941 shares during the period. Finally, Brooklyn Investment Group boosted its holdings in shares of Genmab A/S by 729.3% in the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company’s stock worth $83,000 after purchasing an additional 3,734 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $32.37 on Friday. The company’s fifty day moving average price is $30.56 and its 200-day moving average price is $25.49. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $33.65. The firm has a market capitalization of $20.78 billion, a P/E ratio of 13.77, a PEG ratio of 1.66 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. Genmab A/S has set its FY 2025 guidance at EPS. Equities analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GMAB shares. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. HC Wainwright boosted their price objective on shares of Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a research report on Tuesday, September 23rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.75.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.